Evidence map›Paper›PMID 42657771›Full record

ArticleActa crystallographica. Section D, Structural biology2026

KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches.

Vera Puetter, Léa Bouché, Katrin Nowak-Reppel, Steven J Ferrara, Stefan N Gradl, Daniel Korr, Craig A Strathdee, Antonius Ter Laak, Roman C Hillig

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vera PuetterNuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0001-9065-1322
Léa BouchéResearch & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0001-8523-812X
Katrin Nowak-ReppelNuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany.
Steven J FerraraBroad Institute, Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0009-0009-8275-2321
Stefan N GradlResearch & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0002-7728-1192
Daniel KorrNuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0002-6250-6344
Craig A StrathdeeBroad Institute, Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Antonius Ter LaakResearch & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0003-1820-002X
Roman C HilligNuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany.ORCID 0000-0001-6267-7250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The histone lysine acetyltransferase KAT6A belongs to the MYST family of lysine acetyltransferases which consists of five isoforms. KAT6A (and its paralog KAT6B) have emerged as a promising epigenetic drug targets in cancer, supported by recent clinical data. As support for our high-throughput screening approach aimed at discovering new inhibitors of KAT6A, we developed a crystallization platform system termed KAT6A

Indexed as

Enzyme InhibitorsHistone AcetyltransferasesAcetyl Coenzyme ACatalytic DomainCrystallizationCrystallography, X-RayHumansModels, MolecularAcetyl Coenzyme AEnzyme InhibitorsHistone AcetyltransferasesKAT6A protein, humanback soakingback-soakingsmall-molecule inhibitorsstructure-based drug discoverysurface modificationsurrogate approach

Identifiers

PMID42657771
PMCPMC13532696

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.